Isorhamnetin has been shown to suppress proliferation and induce apoptosis in BC cells by modulating key signaling pathways, including AMPK/mTOR/p70S6K (Yang et al., 2023), Akt, and MEK1/2 (Hu et al., 2015). Here, MAP2K1 is linked to breast cancer.